Status:
COMPLETED
Metabolic Alkalosis in Heart Failure
Lead Sponsor:
Spanish Society of Internal Medicine
Conditions:
Heart Failure
Metabolic Alkalosis
Eligibility:
All Genders
18+ years
Brief Summary
Metabolic alkalosis (MA) is the most common acid-base disorder and when it's severe it can have effects on cellular function and contribute to an increase in mortality. MA is a common complication of...
Eligibility Criteria
Inclusion
- Patient admitted for decompensated HF (main admission diagnosis), who meet the diagnostic criteria of the 2016 European HF Guidelines and who sign the informed consent to participate in the study
- Patients must give their written consent to participate in the study
Exclusion
- Patients whose main reason for admission is not decompensated HF. Those patients who are admitted for another reason and who also have decompensated HF secondarily cannot be included
- Patients who do not strictly meet the diagnostic criteria for HF of the European HF Guidelines.
- Patients for whom analytical values are not available in relation to acid-base balance at the time of admission
- Patients with a pathological history that can clearly justify metabolic alkalosis, such as primary or secondary hyperaldosterism
- Patients who were taking sodium bicarbonate prior to admission
- Patients with factors present at admission that may justify the presence of metabolis alkalosis: vomiting, diarrea, etc.
- Patients who do not give their consent to participate in the study
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
672 Patients enrolled
Trial Details
Trial ID
NCT04740242
Start Date
January 1 2021
End Date
September 30 2021
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Internal Medicine Service, Hospital d'Olot (Girona)
Olot, Girona, Spain, 17800